MedPath

KITE PHARMA, INC.

KITE PHARMA, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
2009-01-01
Employees
1K
Market Cap
-
Website
http://www.kitepharma.com

Clinical Trials

64

Active:36
Completed:9

Trial Phases

3 Phases

Phase 1:44
Phase 2:10
Phase 3:4

Drug Approvals

1

SFDA:1

Drug Approvals

Yescarta

Approval Date
Jul 18, 2025
SFDA

Clinical Trials

Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials

Phase 1
44 (75.9%)
Phase 2
10 (17.2%)
Phase 3
4 (6.9%)

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

Phase 1
Conditions
Systemic Lupus Erythematosus
Lupus Nephritis
Systemic Sclerosis
Idiopathic Inflammatory Myopathy
Interventions
First Posted Date
2025-06-26
Last Posted Date
2025-07-16
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
52
Registration Number
NCT07038447
Locations
🇦🇺

Concord Repatriation General Hospital, Syndey, New South Wales, Australia

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

First Posted Date
2024-05-14
Last Posted Date
2025-08-17
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
450
Registration Number
NCT06413498
Locations
🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 94 locations

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase 2
Active, not recruiting
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Mantle Cell Lymphoma
Interventions
First Posted Date
2024-02-12
Last Posted Date
2025-07-11
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
25
Registration Number
NCT06253663
Locations
🇯🇵

Chiba University Hospital, Chiba, Japan

🇯🇵

Kyushu University Hospital, Fukuoka, Japan

🇯🇵

Hokkaido University Hospital, Hokkaido, Japan

and more 6 locations

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Phase 1
Active, not recruiting
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Interventions
First Posted Date
2023-10-12
Last Posted Date
2025-07-25
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
39
Registration Number
NCT06079164
Locations
🇺🇸

Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States

and more 8 locations

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Conditions
Large B-cell Lymphoma
Follicular Lymphoma
First Posted Date
2023-03-20
Last Posted Date
2025-06-22
Lead Sponsor
Kite, A Gilead Company
Registration Number
NCT05776160
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

and more 110 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

News

CAR T-cell Therapy Monitoring: Study Suggests Reduced REMS May Improve Accessibility

A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.